Cholestasis and fatty liver disease are two distinct liver conditions that can occur independently or together, affecting how your liver processes bile and stores fat. Cholestasis involves reduced or blocked bile flow, leading to accumulation of bile acids and bilirubin, whilst fatty liver disease (now often termed metabolic dysfunction-associated steatotic liver disease, or MASLD) results from excess fat deposits in liver cells. Both conditions are increasingly common in the UK, with fatty liver affecting up to one in three adults. Understanding how these conditions relate to each other is essential for early diagnosis, appropriate treatment, and preventing progression to serious complications such as cirrhosis or liver failure.
Summary: Cholestasis and fatty liver disease are distinct liver conditions that can coexist and influence each other, with cholestasis involving impaired bile flow and fatty liver characterised by excess fat accumulation in liver cells.
- Cholestasis results from reduced bile flow due to obstruction or impaired secretion, causing bile acid and bilirubin accumulation
- Fatty liver disease (MASLD/NAFLD) affects up to one in three UK adults and is strongly associated with obesity, type 2 diabetes, and metabolic syndrome
- Advanced fatty liver disease can develop cholestatic features, whilst retained bile acids from cholestasis may worsen fat accumulation and liver injury
- Diagnosis requires blood tests showing cholestatic patterns (raised ALP, GGT) or hepatocellular injury (raised ALT, AST), plus imaging such as ultrasound or FibroScan
- Treatment for cholestasis may include ursodeoxycholic acid for primary biliary cholangitis, whilst fatty liver management focuses on weight loss, dietary changes, and addressing metabolic risk factors
- Regular monitoring, lifestyle modifications including Mediterranean-style diet and 150 minutes weekly exercise, and specialist referral for high-risk patients are essential for preventing progression
Table of Contents
Am I eligible for weight loss injections?
Find out whether you might be eligible!
Answer a few quick questions to see whether you may be suitable for prescription weight loss injections (like Wegovy® or Mounjaro®).
- No commitment — just a quick suitability check
- Takes about 1 minute to complete
Understanding Cholestasis and Fatty Liver Disease
Cholestasis refers to a reduction or blockage in bile flow from the liver. Bile is a digestive fluid produced by hepatocytes (liver cells) that helps break down fats and eliminate waste products. When bile cannot flow properly—either due to obstruction within the bile ducts (extrahepatic cholestasis, for example from gallstones or pancreatic disease) or impaired secretion at the cellular level (intrahepatic cholestasis)—bile acids and bilirubin accumulate in the liver and bloodstream. This can lead to jaundice, itching, and potential liver damage if left untreated.
Fatty liver disease, medically termed hepatic steatosis, occurs when excess fat accumulates within liver cells. UK hepatology practice now increasingly uses the term metabolic dysfunction-associated steatotic liver disease (MASLD), though non-alcoholic fatty liver disease (NAFLD) remains widely recognised. MASLD/NAFLD is not related to alcohol consumption and is strongly associated with obesity, type 2 diabetes, and metabolic syndrome. Alcohol-related fatty liver disease (AFLD) is caused by excessive alcohol intake. MASLD/NAFLD is common in the UK, affecting up to one in three adults to some degree according to NHS data.
Both conditions represent distinct pathological processes, yet they can coexist and influence one another. Cholestatic features may develop as a complication of advanced fatty liver disease, particularly when inflammation and fibrosis progress to metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) or cirrhosis. It is important to note that many causes of cholestasis—such as gallstones, bile duct strictures, or pancreatic tumours—are unrelated to fatty liver. Understanding the relationship between these conditions is essential for appropriate investigation, management, and prevention of progressive liver injury. Early identification through blood tests and imaging can help guide treatment and prevent serious complications such as liver failure.
How Cholestasis and Fatty Liver Are Connected
The relationship between cholestasis and fatty liver disease is complex. Fatty liver may contribute to cholestatic features through several proposed mechanisms. As fat accumulates in hepatocytes, it may impair the normal function of bile transporters on the cell membrane, potentially reducing bile acid secretion. Inflammation associated with MASH can disrupt bile flow by damaging the intrahepatic bile ducts and altering the expression of genes responsible for bile acid synthesis and transport, though these mechanisms are not fully characterised.
Conversely, cholestasis may worsen fatty liver disease. Retained bile acids are toxic to liver cells and can promote oxidative stress, mitochondrial dysfunction, and inflammation—all of which may accelerate fat accumulation and liver injury. Bile acids also influence lipid metabolism; when their enterohepatic circulation is disrupted, this can lead to abnormal fat handling by the liver.
Advanced liver disease provides another important link. Patients with cirrhosis—whether from MASLD/NAFLD, alcohol, or other causes—often develop cholestatic features due to architectural distortion of the liver and impaired hepatocyte function. Primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) are distinct cholestatic liver diseases that may coexist with MASLD/NAFLD in patients who also have metabolic risk factors, though these are separate conditions rather than causally related.
Certain medications can induce both cholestasis and steatosis, including amiodarone, methotrexate, and some antiretroviral agents. Drug-induced liver injury can present with cholestatic, steatotic, or mixed patterns; a thorough medication review and monitoring under specialist care is essential. Pregnancy-related conditions such as intrahepatic cholestasis of pregnancy (ICP) and acute fatty liver of pregnancy are distinct entities requiring obstetric assessment and management according to RCOG guidance.
Extrahepatic obstruction—such as choledocholithiasis (bile duct stones) or pancreatic head malignancy—is a common cause of cholestasis unrelated to fatty liver and must be considered in the differential diagnosis. Understanding these connections helps clinicians identify the underlying cause and tailor management appropriately.
Symptoms and Diagnosis of Cholestasis with Fatty Liver
Fatty liver disease alone is often asymptomatic, discovered incidentally on blood tests showing elevated liver enzymes (ALT, AST) or on ultrasound imaging performed for other reasons. Some patients report vague right upper quadrant discomfort or fatigue, but these symptoms are non-specific.
Cholestasis produces more distinctive symptoms. Pruritus (itching) is often the earliest and most troublesome symptom, typically worse at night and on the palms and soles. Jaundice (yellowing of the skin and eyes) develops when bilirubin levels rise significantly. Patients may notice dark urine and pale stools due to reduced bile reaching the intestines. Fat-soluble vitamin deficiencies (A, D, E, K) can occur with prolonged cholestasis, potentially causing night blindness, bone pain, or easy bruising.
Urgent medical attention is required if you develop fever, rigors, right upper quadrant pain, and jaundice together, as this may indicate ascending cholangitis requiring same-day hospital assessment. If you are pregnant and develop itching or jaundice, contact your midwife or maternity unit promptly for obstetric assessment.
Diagnosis begins with blood tests. A cholestatic pattern shows elevated alkaline phosphatase (ALP) and gamma-glutamyl transferase (GGT), often with raised bilirubin. GGT helps confirm the hepatic source of raised ALP. Fatty liver typically elevates aminotransferases (ALT more than AST in MASLD/NAFLD; AST more than ALT in alcohol-related liver disease). A comprehensive initial panel in the UK includes:
-
Full blood count, clotting (INR), urea and electrolytes
-
Lipid profile, glucose, and HbA1c to assess metabolic syndrome components
-
Viral hepatitis screen (hepatitis B surface antigen, hepatitis C antibody)
-
Autoimmune liver serology: antimitochondrial antibody (AMA) for PBC, antinuclear antibody (ANA), smooth muscle antibody (SMA), and immunoglobulins
-
Ferritin and transferrin saturation (iron studies)
-
Coeliac serology where clinically indicated
Risk stratification for MASLD/NAFLD uses non-invasive scores. The FIB-4 score (based on age, ALT, AST, and platelet count) helps identify patients at low or high risk of advanced fibrosis. In those under 65 years, FIB-4 <1.3 suggests low risk and >2.67 suggests high risk; age-adjusted thresholds apply for those aged 65 and over. The Enhanced Liver Fibrosis (ELF) test may also be used. NICE NG49 provides clear referral pathways: patients with high-risk scores or uncertain diagnosis should be referred to specialist hepatology services.
Imaging is essential. Ultrasound can detect hepatic steatosis (increased echogenicity) and may identify bile duct dilatation, though it cannot reliably exclude obstruction; persistent suspicion warrants MRCP (magnetic resonance cholangiopancreatography) or ERCP. Transient elastography (FibroScan) measures liver stiffness (fibrosis) and controlled attenuation parameter (CAP score for fat content). MRI with MRCP provides detailed assessment of bile ducts and liver parenchyma.
Liver biopsy may be necessary when the diagnosis is uncertain or to assess disease severity, particularly to distinguish simple steatosis from MASH or to diagnose conditions like PBC. NICE guidance (NG49) and BSG guidelines on abnormal liver blood tests recommend considering specialist referral for patients with suspected advanced fibrosis or unclear aetiology.
Treatment Options for Cholestasis and Fatty Liver
Treatment strategies must address both the underlying causes and the specific complications of each condition.
For cholestasis due to primary biliary cholangitis (PBC), ursodeoxycholic acid (UDCA) is the primary pharmacological treatment. UDCA is a hydrophilic bile acid that improves bile flow, reduces toxic bile acid accumulation, and has anti-inflammatory properties. The typical dose is 13–15 mg/kg/day, as per the MHRA-approved Summary of Product Characteristics. Response is monitored through liver biochemistry; patients showing inadequate response to UDCA or who are intolerant may require second-line agents. Obeticholic acid is licensed for PBC with inadequate UDCA response or UDCA intolerance, but is contraindicated in decompensated cirrhosis or prior decompensation and must be initiated by specialists only. Fibrates (such as bezafibrate) are sometimes used off-label under specialist supervision in PBC. UDCA is not indicated for primary sclerosing cholangitis or for cholestasis in general; treatment of other cholestatic conditions should be guided by specialists.
Pruritus management is crucial for quality of life. First-line treatment includes cholestyramine, a bile acid sequestrant taken before meals and spaced at least four hours from UDCA and other medications to avoid reducing their absorption. Alternatives used off-label include rifampicin (note hepatotoxicity risk and drug interactions via CYP enzyme induction), naltrexone (an opioid antagonist that can precipitate withdrawal in patients taking opioids), or sertraline. Antihistamines are generally ineffective for cholestatic itch. Severe, refractory pruritus may require specialist interventions. Patients should be advised to report any suspected side effects via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk.
For fatty liver disease (MASLD/NAFLD), there is currently no licensed pharmacological treatment in the UK. Management focuses on addressing underlying metabolic factors. Weight loss of 7–10% body weight can significantly reduce liver fat and inflammation. This is achieved through caloric restriction and increased physical activity. Bariatric surgery may be considered for patients with severe obesity. In selected patients with biopsy-proven MASH and advanced fibrosis, specialists may consider pioglitazone or vitamin E under close supervision, as outlined in NICE NG49.
Managing comorbidities is essential: optimising glycaemic control in diabetes and treating dyslipidaemia with statins. Statins are safe in MASLD/NAFLD and reduce cardiovascular risk, which is a major cause of morbidity in these patients. Metformin and GLP-1 receptor agonists are indicated for type 2 diabetes and obesity respectively (per NICE guidance), but should not be prescribed solely for liver disease. Hypertension should be controlled according to standard guidelines.
Vitamin supplementation is important in cholestasis. Fat-soluble vitamins (A, D, E, K) should be monitored and replaced as needed. Calcium and vitamin D supplementation helps prevent metabolic bone disease. In patients with troublesome steatorrhoea (fatty stools) due to cholestasis, medium-chain triglyceride (MCT) supplements or MCT-rich dietary options may be considered under dietetic advice.
Treating advanced disease: Patients with decompensated cirrhosis or liver failure may require liver transplantation. Both cholestatic diseases and MASH-related cirrhosis are accepted indications for transplantation in the UK.
Managing Your Liver Health: Lifestyle and Monitoring
Lifestyle modifications form the cornerstone of managing both conditions and preventing progression.
Dietary changes are fundamental. Adopt a Mediterranean-style diet rich in vegetables, fruits, whole grains, legumes, nuts, and olive oil, with moderate fish consumption and limited red meat. Reduce intake of refined carbohydrates, sugary drinks, and processed foods. For cholestasis, a low-fat diet may reduce steatorrhoea (fatty stools), though moderate healthy fat intake is generally acceptable. Alcohol: UK Chief Medical Officers advise not regularly exceeding 14 units per week, spread over three or more days. However, abstinence is strongly recommended for anyone with steatohepatitis, advanced fibrosis, cirrhosis, or alcohol-related liver disease.
Physical activity improves insulin sensitivity and promotes weight loss. NHS guidance recommends at least 150 minutes of moderate-intensity aerobic activity weekly (such as brisk walking, cycling, or swimming), plus strength training twice weekly. Even without weight loss, exercise reduces liver fat and inflammation.
Weight management requires realistic, sustainable goals. Aim for gradual weight loss of 0.5–1 kg per week. Rapid weight loss can paradoxically worsen liver inflammation. Referral to dietitians or weight management services may be beneficial.
Immunisation is important for people with chronic liver disease. Ensure you are up to date with hepatitis A and B, influenza, and pneumococcal vaccinations as recommended in the UKHSA Green Book.
Regular monitoring is essential and should be tailored to your fibrosis stage and comorbidities. Your GP will arrange periodic blood tests to assess liver function, check for disease progression, and monitor for complications. Patients with cirrhosis require specialist-led care, including surveillance for hepatocellular carcinoma (liver cancer) with ultrasound every six months, with or without alpha-fetoprotein (AFP) blood testing depending on local protocols. Endoscopic screening for oesophageal varices may be necessary, guided by non-invasive markers and specialist assessment.
When to seek medical attention: Contact your GP promptly if you develop new or worsening jaundice, increasing abdominal swelling, confusion, vomiting blood, or black tarry stools—these may indicate serious complications requiring urgent assessment. Worsening itching despite treatment also warrants review. Seek same-day hospital assessment if you develop fever, rigors, right upper quadrant pain, and jaundice together, as this may indicate ascending cholangitis. If you are pregnant and develop itching or jaundice, contact your midwife or maternity unit immediately for obstetric assessment.
Medication review is important, as many drugs are metabolised by the liver. Always inform healthcare professionals about your liver condition before starting new medications. Avoid hepatotoxic substances and herbal supplements without medical advice, as some can cause significant liver injury.
Frequently Asked Questions
Can fatty liver disease cause cholestasis?
Yes, advanced fatty liver disease can develop cholestatic features, particularly when inflammation and fibrosis progress to metabolic dysfunction-associated steatohepatitis (MASH) or cirrhosis. Fat accumulation in liver cells may impair bile transporter function and reduce bile acid secretion, whilst inflammation can damage intrahepatic bile ducts and disrupt bile flow.
What are the warning signs that my cholestasis or fatty liver is getting worse?
Warning signs include new or worsening jaundice (yellowing of skin and eyes), increasing abdominal swelling, confusion, vomiting blood, or black tarry stools, all of which require urgent medical assessment. Worsening itching despite treatment, persistent right upper quadrant pain, or unexplained weight loss also warrant prompt GP review.
How is cholestasis with fatty liver diagnosed?
Diagnosis involves blood tests showing elevated alkaline phosphatase (ALP) and gamma-glutamyl transferase (GGT) for cholestasis, plus raised aminotransferases (ALT, AST) for fatty liver, alongside imaging such as ultrasound or FibroScan. Additional tests include autoimmune serology, viral hepatitis screening, and risk stratification scores like FIB-4 to assess fibrosis severity and guide specialist referral.
What's the difference between cholestasis and cirrhosis?
Cholestasis refers to impaired bile flow causing bile acid accumulation, whilst cirrhosis is advanced scarring (fibrosis) of the liver from chronic injury that distorts liver architecture and impairs function. Cholestasis can be a feature of cirrhosis, but many causes of cholestasis (such as gallstones or primary biliary cholangitis) occur without cirrhosis, and cirrhosis can develop from non-cholestatic conditions like fatty liver disease.
Can I take statins if I have fatty liver and cholestasis?
Yes, statins are generally safe in fatty liver disease and reduce cardiovascular risk, which is a major cause of morbidity in these patients. However, liver function should be monitored, and any patient with cholestasis or abnormal liver tests should have statin therapy reviewed by their GP or specialist to ensure appropriate monitoring and dosing.
When should I be referred to a liver specialist for cholestasis or fatty liver?
Referral to hepatology is recommended if you have high-risk fibrosis scores (FIB-4 >2.67 in under-65s or age-adjusted thresholds), uncertain diagnosis, persistent abnormal liver tests despite lifestyle changes, or features suggesting advanced disease such as jaundice, ascites, or varices. NICE guidance (NG49) provides clear referral pathways based on non-invasive risk stratification.
The health-related content published on this site is based on credible scientific sources and is periodically reviewed to ensure accuracy and relevance. Although we aim to reflect the most current medical knowledge, the material is meant for general education and awareness only.
The information on this site is not a substitute for professional medical advice. For any health concerns, please speak with a qualified medical professional. By using this information, you acknowledge responsibility for any decisions made and understand we are not liable for any consequences that may result.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Heading 6
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Block quote
Ordered list
- Item 1
- Item 2
- Item 3
Unordered list
- Item A
- Item B
- Item C
Bold text
Emphasis
Superscript
Subscript
